These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28177196)

  • 1. End-stage renal disease and adherence to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among patients with diabetes.
    Shani M; Vinker S; Feldman L
    J Clin Hypertens (Greenwich); 2017 Jun; 19(6):627-631. PubMed ID: 28177196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
    Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
    Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Pharmacist Telephone Intervention to Identify Adherence Barriers and Improve Adherence Among Nonadherent Patients with Comorbid Hypertension and Diabetes in a Medicare Advantage Plan.
    Abughosh SM; Wang X; Serna O; Henges C; Masilamani S; Essien EJ; Chung N; Fleming M
    J Manag Care Spec Pharm; 2016 Jan; 22(1):63-73. PubMed ID: 27015053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EVALUATING THE PRESCRIPTION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR RECEPTOR BLOCKERS IN PATIENTS WITH DIABETES IN JORDAN.
    Mayyas F; Bataineh W; Jarab A
    Endocr Pract; 2017 Nov; 23(11):1289-1296. PubMed ID: 28816537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria.
    Hsu FY; Lin FJ; Ou HT; Huang SH; Wang CC
    Kidney Blood Press Res; 2017; 42(2):358-368. PubMed ID: 28618426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease.
    Wang PT; Huang YB; Lin MY; Chuang PF; Hwang SJ
    Kaohsiung J Med Sci; 2012 Sep; 28(9):477-83. PubMed ID: 22974666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of individual renin-angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: a network meta-analysis.
    Cai J; Huang X; Zheng Z; Lin Q; Peng M; Shen D
    Nephrol Dial Transplant; 2018 Nov; 33(11):1968-1976. PubMed ID: 29579289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: A 15-year cohort study.
    Wu HY; Peng CL; Chen PC; Chiang CK; Chang CJ; Huang JW; Peng YS; Tu YK; Chu TS; Hung KY; Chien KL
    PLoS One; 2017; 12(5):e0177654. PubMed ID: 28505194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonadherence to angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs.
    Yang Y; Thumula V; Pace PF; Banahan BF; Wilkin NE; Lobb WB
    J Am Pharm Assoc (2003); 2010; 50(4):527-31. PubMed ID: 20621872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
    Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
    Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for end-stage renal disease/mortality in type 2 diabetes.
    Campbell HM; Khan N; Raisch DW; Borrego ME; Sather MR; Murata GH
    Diabetes Res Clin Pract; 2013 Dec; 102(3):233-41. PubMed ID: 24183258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis.
    Lin TT; Yang YH; Liao MT; Tsai CT; Hwang JJ; Chiang FT; Chen PC; Lin JL; Lin LY
    Kidney Int; 2015 Aug; 88(2):378-85. PubMed ID: 25807037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of renin-angiotensin system blockers on renal and cardiovascular outcomes in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
    Liu X; Ma L; Li Z
    J Endocrinol Invest; 2020 Jul; 43(7):959-972. PubMed ID: 31939197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship Between Medication Adherence and Distance to Dispensing Pharmacies and Prescribers Among an Urban Medicaid Population with Diabetes Mellitus.
    Syed ST; Sharp LK; Kim Y; Jentleson A; Lora CM; Touchette DR; Berbaum ML; Suda KJ; Gerber BS
    Pharmacotherapy; 2016 Jun; 36(6):590-7. PubMed ID: 27087250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With Outcomes After Acute Kidney Injury.
    Brar S; Ye F; James MT; Hemmelgarn B; Klarenbach S; Pannu N;
    JAMA Intern Med; 2018 Dec; 178(12):1681-1690. PubMed ID: 30422153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Motivational Interviewing Intervention to Improve Adherence to ACEIs/ARBs among Nonadherent Older Adults with Comorbid Hypertension and Diabetes.
    Mohan A; Majd Z; Johnson ML; Essien EJ; Barner J; Serna O; Gallardo E; Fleming ML; Ordonez N; Holstad MM; Abughosh SM
    Drugs Aging; 2023 Apr; 40(4):377-390. PubMed ID: 36847995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
    Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
    JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for renal outcomes and mortality in diabetic kidney disease.
    Jiang S; Fang J; Yu T; Li W
    Eur J Intern Med; 2021 Mar; 85():127-129. PubMed ID: 33250340
    [No Abstract]   [Full Text] [Related]  

  • 20. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
    Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.